Drug intelligence / Profile preview

cucumarioside A2-2

Development stage: Preclinical
Modality: Small Molecules
Administration: Intraperitoneal

Overview

Cucumarioside A2-2 is a marine triterpene glycoside investigated preclinically as an anticancer agent, particularly in castration-resistant prostate cancer. In the cited in vitro PC-3 prostate cancer model, it induced G2/M cell-cycle arrest, triggered caspase-dependent intrinsic apoptosis, and inhibited colony formation and growth at low micromolar concentrations. Its mechanism appears pleiotropic rather than target-defined, with proteomic changes linked to metastatic potential, invasion, and apoptosis, including altered keratin 81, CrkII, IL-1β, and cathepsin B. No evidence from the provided context supports clinical development, commercialization, or a named corporate developer.

Other names: cucumarioside A2-2cucumarioside A

Beyond the preview

Go deeper on cucumarioside A2-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cucumarioside A2-2.

Explore the full profile